Bronchiectasis in a patient with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy: a case report.
APECED
APS-1
Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy
Autoimmune pneumonitis
Autoimmune polyendocrine Syndrome-1
Bronchiectasis
Case report
Treatable traits
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
23
02
2024
accepted:
03
07
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
The rare monogenic syndrome Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) leads to multisystemic autoimmunity with possible lung involvement. Autoimmune pneumonitis is a rare manifestation, with bronchiectasis being the most frequent radiologic pattern, and may lead to fatal outcome. The Sardinian population in Italy has a high incidence of APECED, although no case of lung manifestation has been reported yet in this cohort. This is the case of a Sardinian APECED patient referred to a bronchiectasis clinic. Our aim is to raise awareness and screen these patients earlier for pulmonary involvement and to initiate multidisciplinary treatment for better outcome. A 49-year-old female native of Sardinia from consanguineous parents was diagnosed with APECED in childhood and was referred to our bronchiectasis clinic in March 2023. In addition to typical APECED features, she reported recurrent respiratory infections since childhood, chronic purulent sputum and a hospitalization for pneumonia. She came to our attention with a recent isolation of P. aeruginosa on sputum culture and diffuse cylindrical and varicoid bronchiectasis on her first CT scan. She underwent aetiologic screening for bronchiectasis with no evidence of another cause of disease. Lung treatment was optimized according to bronchiectasis guidelines, and during follow-up the patient developed methicillin-resistant Staphylococcus aureus (MRSA) infection and M. intracellulare pulmonary disease. The patient was offered P. aeruginosa eradication treatment with intravenous antibiotics and initiation of antimycobacterial therapy. This is the first documented lung involvement case of APECED in a Sardinian patient, and the first patient reported to enter a bronchiectasis program. The patient was prescribed lung imaging late in time when bronchiectasis complications were already present. Our case report highlights the need for early pulmonary screening and multidisciplinary management in patients with APECED.
Sections du résumé
BACKGROUND
BACKGROUND
The rare monogenic syndrome Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) leads to multisystemic autoimmunity with possible lung involvement. Autoimmune pneumonitis is a rare manifestation, with bronchiectasis being the most frequent radiologic pattern, and may lead to fatal outcome. The Sardinian population in Italy has a high incidence of APECED, although no case of lung manifestation has been reported yet in this cohort. This is the case of a Sardinian APECED patient referred to a bronchiectasis clinic. Our aim is to raise awareness and screen these patients earlier for pulmonary involvement and to initiate multidisciplinary treatment for better outcome.
CASE PRESENTATION
METHODS
A 49-year-old female native of Sardinia from consanguineous parents was diagnosed with APECED in childhood and was referred to our bronchiectasis clinic in March 2023. In addition to typical APECED features, she reported recurrent respiratory infections since childhood, chronic purulent sputum and a hospitalization for pneumonia. She came to our attention with a recent isolation of P. aeruginosa on sputum culture and diffuse cylindrical and varicoid bronchiectasis on her first CT scan. She underwent aetiologic screening for bronchiectasis with no evidence of another cause of disease. Lung treatment was optimized according to bronchiectasis guidelines, and during follow-up the patient developed methicillin-resistant Staphylococcus aureus (MRSA) infection and M. intracellulare pulmonary disease. The patient was offered P. aeruginosa eradication treatment with intravenous antibiotics and initiation of antimycobacterial therapy.
CONCLUSION
CONCLUSIONS
This is the first documented lung involvement case of APECED in a Sardinian patient, and the first patient reported to enter a bronchiectasis program. The patient was prescribed lung imaging late in time when bronchiectasis complications were already present. Our case report highlights the need for early pulmonary screening and multidisciplinary management in patients with APECED.
Identifiants
pubmed: 39478519
doi: 10.1186/s12890-024-03149-9
pii: 10.1186/s12890-024-03149-9
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543Informations de copyright
© 2024. The Author(s).
Références
Bruserud Ø, Oftedal BE, Wolff AB, Husebye ES. AIRE-mutations and autoimmune disease. Curr Opin Immunol. 2016;43:8–15. https://doi.org/10.1016/j.coi.2016.07.003 .
doi: 10.1016/j.coi.2016.07.003
pubmed: 27504588
Anderson MS, Su MA. AIRE expands: new roles in immune tolerance and beyond. Nat Rev Immunol. 2016;16(4):247–58. https://doi.org/10.1038/nri.2016.9 .
doi: 10.1038/nri.2016.9
pubmed: 26972725
pmcid: 4831132
Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322(26):1829–36. https://doi.org/10.1056/NEJM199006283222601 .
doi: 10.1056/NEJM199006283222601
pubmed: 2348835
Ferre EMN, Rose SR, Rosenzweig SD, Burbelo PD, Romito KR, Niemela JE, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016;1(13). https://doi.org/10.1172/jci.insight.88782 .
Constantine GM, Lionakis MS. Lessons from primary immunodeficiencies: autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Immunol Rev. 2019;287(1):103–20. https://doi.org/10.1111/imr.12714 .
doi: 10.1111/imr.12714
pubmed: 30565240
pmcid: 6309421
Ferré EMN, Break TJ, Burbelo PD, Allgäuer M, Kleiner DE, Jin D, et al. Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Sci Transl Med. 2019;11(495):eaav5597. https://doi.org/10.1126/scitranslmed.aav5597 .
doi: 10.1126/scitranslmed.aav5597
pubmed: 31167928
pmcid: 6647037
De Luca F, Valenzise M, Alaggio R, Arrigo T, Crisafulli G, Salzano G, et al. Sicilian family with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and lethal lung disease in one of the affected brothers. Eur J Pediatr. 2008;167(11):1283–8. https://doi.org/10.1007/s00431-008-0668-3 .
doi: 10.1007/s00431-008-0668-3
pubmed: 18274776
Kubala SA, Do HM, Ferré EMN, Schrump DS, Olivier KN, Walls JG, et al. Fatal autoimmune pneumonitis requiring bilobectomy and omental flap repair in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Respir Med Case Rep. 2021;33(101476):101476. https://doi.org/10.1016/j.rmcr.2021.101476 .
doi: 10.1016/j.rmcr.2021.101476
pubmed: 34401309
pmcid: 8349050
Alimohammadi M, Dubois N, Sköldberg F, Hallgren A, Tardivel I, Hedstrand H, et al. Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proc Natl Acad Sci U S A. 2009;106(11):4396–401. https://doi.org/10.1073/pnas.0809986106 .
doi: 10.1073/pnas.0809986106
pubmed: 19251657
pmcid: 2648890
Popler J, Alimohammadi M, Kämpe O, Dalin F, Dishop MK, Barker JM, et al. Autoimmune polyendocrine syndrome type 1: utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatr Pulmonol. 2012;47(1):84–7. https://doi.org/10.1002/ppul.21520 .
doi: 10.1002/ppul.21520
pubmed: 21901851
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3). https://doi.org/10.1183/13993003.00629-2017 .
Aliberti S, Goeminne PC, O’Donnell AE, Aksamit TR, Al-Jahdali H, Barker AF, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. 2022;10(3):298–306. https://doi.org/10.1016/S2213-2600(21)00277-0 .
doi: 10.1016/S2213-2600(21)00277-0
pubmed: 34570994
Cole PJ. Inflammation: a two-edged sword–the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6–15.
pubmed: 3533593
Aliberti S, Amati F, Gramegna A, Vigone B, Oriano M, Sotgiu G, et al. Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients. ERJ Open Res. 2022;8(1):00388–2021. https://doi.org/10.1183/23120541.00388-2021 .
doi: 10.1183/23120541.00388-2021
pubmed: 35350277
pmcid: 8958217
Amati F, Simonetta E, Pilocane T, Gramegna A, Goeminne P, Oriano M, et al. Diagnosis and initial investigation of bronchiectasis. Semin Respir Crit Care Med. 2021;42(4):513–24. https://doi.org/10.1055/s-0041-1730892 .
doi: 10.1055/s-0041-1730892
pubmed: 34261176
Boaventura R, Sibila O, Agusti A, Chalmers JD. Treatable traits in bronchiectasis. Eur Respir J. 2018;52(3):1801269. https://doi.org/10.1183/13993003.01269-2018 .
doi: 10.1183/13993003.01269-2018
pubmed: 30190263
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85. https://doi.org/10.1164/rccm.201309-1575OC .
doi: 10.1164/rccm.201309-1575OC
pubmed: 24328736
pmcid: 3977711
Meloni A, Willcox N, Meager A, Atzeni M, Wolff ASB, Husebye ES, et al. Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in sardinian patients. J Clin Endocrinol Metab. 2012;97(4):1114–24. https://doi.org/10.1210/jc.2011-2461 .
doi: 10.1210/jc.2011-2461
pubmed: 22344197
Anwar GA, McDonnell MJ, Worthy SA, Bourke SC, Afolabi G, Lordan J, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med. 2013;107(7):1001–7. https://doi.org/10.1016/j.rmed.2013.04.013 .
doi: 10.1016/j.rmed.2013.04.013
pubmed: 23672995
Girón RM, de Gracia Roldán J, Olveira C, Vendrell M, Martínez-García MÁ, de la Rosa D, et al. Sex bias in diagnostic delay in bronchiectasis: an analysis of the Spanish historical Registry of Bronchiectasis. Chron Respir Dis. 2017;14(4):360–9. https://doi.org/10.1177/1479972317702139 .
doi: 10.1177/1479972317702139
pubmed: 28393532
pmcid: 5729731
Chessari C, Simonetta E, Amati F, Nigro M, Stainer A, Sotgiu G et al. Diagnostic delay in bronchiectasis: an Italian perspective. ERJ Open Res. 10(2):00713–2023. https://pubmed.ncbi.nlm.nih.gov/38500794/ .
Ferré EMN, Schmitt MM, Lionakis MS. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Front Pediatr. 2021;9. https://doi.org/10.3389/fped.2021.723532 .
Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127–37. https://doi.org/10.1056/NEJMoa2021713 .
doi: 10.1056/NEJMoa2021713
pubmed: 32897034
Chalmers JD, Metersky ML, Feliciano J, Fernandez C, Teper A, Maes A, et al. Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis. ERJ Open Res. 2023;9(3):00695–2022. https://doi.org/10.1183/23120541.00695-2022 .
doi: 10.1183/23120541.00695-2022
pubmed: 37143828
pmcid: 10152260